E
Spyre Therapeutics, Inc. SYRE
$34.09 $0.100.29% NASDAQ
Recommendation
Prev Close
$33.99
Volume
847,479
Avg Vol (90D)
875,676
Market Cap
$2.64B
Dividend & Yield
--
52-Week Range
$10.91 - $35.31
P/E (TTM)
--
EPS (TTM)
-$1.20
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Spyre Therapeutics (SYRE, $33.73) Moving Average Convergence Divergence (MACD) Histogram turned positive on January 20, 2026
1/21/2026 - Tickeron - Technical Analysis
Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Spyre Therapeutics (SYRE) and Astellas Pharma (OtherALPMF)
1/19/2026 - TipRanks Financial Blog
How Does Spyre Therapeutics' New CCO Shape SYRE's Path From Pipeline To Commercial Strategy?
1/16/2026 - Simply Wall St
Spyre Therapeutics (NASDAQ:SYRE) Receives "Buy" Rating from BTIG Research
1/16/2026 - MarketBeat
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating
1/15/2026 - Insider Monkey
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating
1/15/2026 - Yahoo! Finance: News
Spyre Therapeutics (NASDAQ:SYRE) Trading 7.7% Higher - What's Next?
1/14/2026 - Ticker Report
Spyre Therapeutics (NASDAQ:SYRE) Trading 7.7% Higher - What's Next?
1/14/2026 - MarketBeat
Spyre Therapeutics (SYRE, $31.53) Aroon Indicator entered a Downtrend on January 13, 2026.
1/14/2026 - Tickeron - Stocks
Spyre Therapeutics (SYRE) Valuation After New Trial Milestones And Commercial Leadership Appointment
1/13/2026 - Simply Wall St
Spyre Therapeutics (SYRE, $32.8) Aroon Indicator entered a Downtrend on January 12, 2026.
1/13/2026 - Tickeron - Stocks
Spyre Therapeutics Accelerates SKYLINE Trial and Bolsters Leadership
1/12/2026 - TipRanks Financial Blog
Spyre Therapeutics highlights 2026 priorities, appoints Cheveln as CCO
1/12/2026 - TipRanks Financial Blog
Spyre Therapeutics highlights 2026 priorities, appoints Cheveln as CCO
1/12/2026 - The Fly
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts ...
1/12/2026 - GuruFocus
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
1/12/2026 - Globe Newswire
Spyre Therapeutics' CEO Sells 15,000 Shares
1/11/2026 - Nasdaq News: Markets
Spyre Therapeutics' CEO Sells 15,000 Shares
1/11/2026 - Fool.com Headlines
Spyre Therapeutics Announces Grants of Inducement Awards
1/8/2026 - GuruFocus
Spyre Therapeutics Announces Grants of Inducement Awards
1/8/2026 - Globe Newswire
Spyre Therapeutics (SYRE, $31.05) Stochastic Oscillator left the oversold zone on January 07, 2026
1/8/2026 - Tickeron - Stocks
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Brokerages
1/8/2026 - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) CEO Sells $460,200.00 in Stock
1/7/2026 - MarketBeat
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock
1/7/2026 - MarketBeat
Spyre Therapeutics (SYRE) Valuation Check After Recent Drop And Focus On 2026 Trial Readouts
1/6/2026 - Simply Wall St
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$61.07M
EBIT (TTM)
-$223.64M
Net Income (TTM)
-$148.97M
Balance Sheet
Total Assets (Q)
$504.60M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$49.50M
Book Value Per Share (Q)
$4.95
Cash Flow
Cash from Operations (TTM)
-$161.87M
Cash from Investing (TTM)
-$66.61M
Cash from Financing (TTM)
$221.81M
Net Change in Cash (TTM)
-$6.68M
Filings
Filing Date
Tuesday, November 4, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
2.46
7-Day Total Return
3.93%
30-Day Total Return
-1.56%
60-Day Total Return
45.87%
90-Day Total Return
117.83%
Year to Date Total Return
11.48%
1-Year Total Return
56.23%
2-Year Total Return
25.65%
3-Year Total Return
164.83%
5-Year Total Return
-82.13%
52-week Low
Apr 09, 2025 - $10.91
52-week High
Dec 11, 2025 - $35.31
Valuation
Market Cap
$2.64B - Mid Cap
Enterprise Value
$2.31B
Price/Sales (TTM)
--
Price/Book (Q)
6.87
Dividends and Shares
Shares Outstanding
60.41M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.spyre.com
Phone Number
617 651 5940
Address
221 Crescent Street
Building 23 - Suite 105
Waltham, MA 02453
Country
United States
Year Founded
2013
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human... more
NASDAQ 01/22/2026 4:00PM Eastern Quotes delayed